AOD-9604 is a synthetic peptide fragment derived from the C-terminal region of human growth hormone (hGH 176–191) that has been studied primarily for its potential lipolytic (fat-reducing) properties. While preclinical and some clinical research suggest it may stimulate fat metabolism without the adverse effects associated with full-length growth hormone, the body of evidence remains limited, and AOD-9604 is not approved as a therapeutic drug for fat loss in most jurisdictions. Researchers interested in this compound should carefully evaluate the existing literature and understand its regulatory status before incorporating it into any protocol.
AOD-9604 has emerged as one of the most frequently discussed peptides in the fat loss research space. Originally developed by Metabolic Pharmaceuticals in Australia, this modified fragment of human growth hormone was designed to isolate the lipolytic activity of hGH while minimizing its growth-promoting and diabetogenic effects. This AOD-9604 fat loss peptide research guide provides a comprehensive overview of the compound’s mechanism of action, available research data, reported dosing protocols, and key considerations for anyone evaluating its scientific profile.
As interest in peptide-based metabolic research continues to grow, AOD-9604 occupies a unique position — it has undergone more formal clinical investigation than many research peptides, yet its development pathway has been complex and, at times, controversial. Understanding what the science actually shows is essential for any informed researcher.
What Is AOD-9604? Origin and Chemical Profile
AOD-9604, also known as Anti-Obesity Drug 9604, is a synthetic analog of the fragment spanning amino acids 176 to 191 of human growth hormone. It consists of 16 amino acids from the tail end of the hGH molecule, with a tyrosine residue added at the N-terminus to improve stability. The resulting peptide has a molecular weight of approximately 1,817.12 Da and the molecular formula C78H123N23O23S2.
The peptide was developed in the 1990s by Professor Frank Ng and his research team at Monash University in Melbourne, Australia. Their hypothesis was that specific regions of the growth hormone molecule were responsible for distinct biological activities, and that the C-terminal fragment could be isolated to promote fat metabolism independently of the growth-stimulating properties of full-length hGH.
Unlike recombinant human growth hormone, AOD-9604 does not bind to the growth hormone receptor in a manner that triggers IGF-1 elevation, cellular proliferation, or the insulin resistance commonly associated with exogenous hGH administration. This distinction is central to its research interest — the potential to modulate fat metabolism without systemic growth hormone side effects.
Mechanism of Action: How AOD-9604 May Influence Fat Metabolism
The proposed mechanism of action for AOD-9604 centers on the stimulation of lipolysis (the breakdown of stored triglycerides into free fatty acids and glycerol) and the inhibition of lipogenesis (the process by which the body converts non-fat food sources into stored body fat). Research conducted in animal models and in vitro studies has provided the foundational understanding of these mechanisms.
In preclinical studies, AOD-9604 appeared to act on adipose tissue through a pathway involving beta-3 adrenergic receptor activity and the modulation of fat cell metabolism. Specifically, the peptide was observed to:
Stimulate lipolysis: In studies using both murine and human fat cell cultures, AOD-9604 increased the rate of fat breakdown. This effect was observed to be comparable to the lipolytic activity of full-length hGH in some experimental conditions.
Inhibit lipogenesis: The peptide also appeared to reduce the rate at which new fat was synthesized and stored, suggesting a dual mechanism that both promotes fat release and limits fat accumulation.
Avoid hGH-related side effects: Critically, in the studied models, AOD-9604 did not produce hyperglycemia, did not significantly alter IGF-1 levels, and did not promote tissue or organ growth — effects commonly associated with full-length growth hormone therapy.
It is important to note that the precise molecular target and full signaling cascade of AOD-9604 have not been completely elucidated. Some researchers have suggested the involvement of a distinct, as-yet-uncharacterized receptor, while others propose that the peptide interacts with components of the existing growth hormone signaling pathway in a selective manner.
Overview of Published Research and Clinical Trials
AOD-9604 has a more substantial research history than many peptides currently discussed in the research community. Below is a summary of key studies and clinical data points:
| Study / Phase | Model | Key Findings | Limitations |
|---|---|---|---|
| Ng & Borner (early preclinical, 1990s) | Obese mice (ob/ob) | Significant reduction in body fat over 14–19 days of treatment; no effect on lean mass or blood glucose | Animal model; limited translational applicability |
| In vitro adipocyte studies | Human and murine fat cells | Increased lipolysis and decreased lipogenesis; effects comparable to hGH fragment | Cell culture conditions may not reflect in vivo dynamics |
| Phase IIa Clinical Trial (Metabolic Pharmaceuticals) | Obese human subjects (oral formulation) | Modest but statistically non-significant weight reduction in some dosage groups over 12 weeks | Oral bioavailability concerns; study underpowered |
| Phase IIb Clinical Trial (~2007) | Over 500 obese subjects (oral formulation) | Failed to demonstrate statistically significant weight loss compared to placebo | Oral delivery likely reduced efficacy; trial design questioned by some researchers |
| TGA (Australia) review for GRAS status | Safety review | Granted Generally Recognized as Safe (GRAS) status for use in food products (not as a drug) | GRAS status does not equate to therapeutic approval |
The clinical trial results deserve careful interpretation. The Phase IIb trial, which used an oral formulation, did not meet its primary endpoint of significant weight loss. However, many researchers have noted that oral delivery of a peptide of this size presents significant bioavailability challenges. Peptides are typically degraded in the gastrointestinal tract, and the failure of the oral formulation may reflect a delivery problem rather than a fundamental lack of biological activity. Subcutaneous injection, the route used in most current research protocols, may provide substantially different pharmacokinetic outcomes, though large-scale controlled clinical data on injected AOD-9604 for fat loss remain lacking.
Commonly Referenced Dosing Protocols in Research
It is essential to emphasize that there are no universally approved or standardized dosing guidelines for AOD-9604, as it is not an approved pharmaceutical drug for fat loss. The following table reflects dosing ranges commonly referenced in research literature and community-reported protocols. These should not be interpreted as medical recommendations.
| Parameter | Commonly Referenced Range | Notes |
|---|---|---|
| Dose per administration | 250–500 mcg | Most research references cite 300 mcg as a common starting point |
| Frequency | Once daily | Typically administered in the morning on an empty stomach |
| Route of administration | Subcutaneous injection | Preferred over oral due to bioavailability considerations |
| Protocol duration | 8–12 weeks | Longer durations referenced in some protocols; cycling is common |
| Reconstitution | Bacteriostatic water | Typical reconstitution volume: 1–2 mL per 5 mg vial |
| Storage (reconstituted) | Refrigerated (2–8°C) | Use within 25–30 days after reconstitution |
Researchers frequently note that AOD-9604 is often administered in a fasted state, with the rationale that food intake — particularly carbohydrates — may blunt the lipolytic response. Some protocols also reference combining AOD-9604 with other peptides such as CJC-1295 or Ipamorelin, though the synergistic effects of such combinations have not been rigorously studied in controlled settings.
Track your peptide protocol
Log every dose, cost, and observation in one organized spreadsheet.
Safety Profile and Reported Side Effects
One of the most frequently cited advantages of AOD-9604 in the research literature is its favorable safety profile relative to full-length growth hormone. In clinical trials conducted by Metabolic Pharmaceuticals, the compound was reported to be well-tolerated, with no serious adverse events attributed directly to the peptide.
Key safety observations from available data include:
No significant impact on blood glucose: Unlike exogenous hGH, AOD-9604 has not been associated with hyperglycemia or insulin resistance in the studies conducted to date.
No elevation of IGF-1: The peptide does not appear to raise insulin-like growth factor 1 levels, which is relevant because chronic IGF-1 elevation has been linked to potential long-term health risks including cellular proliferation.
No anti-hGH antibody formation: Studied subjects did not develop antibodies against human growth hormone, suggesting the fragment does not provoke an immune response that would cross-react with endogenous hGH.
Injection site reactions: As with most subcutaneously administered peptides, minor redness, swelling, or discomfort at the injection site has been anecdotally reported.
However, it is critical to acknowledge that the long-term safety of AOD-9604, particularly when administered via subcutaneous injection over extended periods, has not been established through large-scale, multi-year clinical studies. Researchers should exercise appropriate caution and recognize the limitations of the existing safety data.
Regulatory Status and Legal Considerations
The regulatory landscape surrounding AOD-9604 is nuanced and varies by jurisdiction. In Australia, the peptide was granted GRAS (Generally Recognized as Safe) status by the Therapeutic Goods Administration (TGA) in 2010 — but this designation was specific to its use as an ingredient in food products, not as a therapeutic agent for weight loss or any other medical condition.
In the United States, AOD-9604 is not FDA-approved for any therapeutic indication. It is available through compounding pharmacies and peptide research suppliers, but its sale is typically designated for research purposes only or prescribed off-label by licensed practitioners. The World Anti-Doping Agency (WADA) has classified AOD-9604 as a prohibited substance under the category of growth hormone releasing factors and peptide hormones, which is relevant for competitive athletes.
Researchers and individuals should verify the specific legal status of AOD-9604 in their jurisdiction before obtaining or using it in any context.
Comparison with Other Fat Loss Peptides
AOD-9604 is often discussed alongside other peptides that have been studied for metabolic or body composition effects. Understanding how it compares can help researchers contextualize its potential role.
| Peptide | Primary Mechanism | IGF-1 Impact | Level of Clinical Evidence |
|---|---|---|---|
| AOD-9604 | Direct lipolysis stimulation, lipogenesis inhibition | Minimal / None | Phase II clinical trials (oral); preclinical (injection) |
| HGH Fragment 176-191 | Similar to AOD-9604 (parent compound without tyrosine modification) | Minimal / None | Primarily preclinical |
| Tesamorelin | GHRH analog; increases endogenous GH secretion | Elevates IGF-1 | FDA-approved for HIV-associated lipodystrophy |
| CJC-1295 / Ipamorelin | GH secretagogues; increase pulsatile GH release | Elevates IGF-1 | Clinical trials conducted; not FDA-approved for fat loss |
| 5-Amino-1MQ | NNMT inhibitor; targets cellular energy metabolism | None reported | Primarily preclinical |
AOD-9604’s distinguishing characteristic in this landscape is its purported ability to influence fat metabolism without elevating IGF-1 or triggering broader growth hormone pathways. This selectivity, if consistently demonstrated in further research, could represent a meaningful advantage for individuals concerned about the systemic effects of growth hormone stimulation.
Current Gaps in Research and Future Directions
Despite the promising preclinical data, several significant gaps remain in the AOD-9604 evidence base. The failure of oral formulations in Phase II trials left unresolved questions about whether the peptide would perform differently when delivered subcutaneously in a rigorous, placebo-controlled clinical setting. To date, no large-scale randomized controlled trial has evaluated injected AOD-9604 specifically for fat reduction in human subjects.
Additionally, the exact molecular receptor or binding site through which AOD-9604 exerts its lipolytic effects has not been definitively identified. Clarifying this mechanism would not only validate the compound’s biological activity but could also open pathways to more targeted peptide development in the future.
Other areas warranting further investigation include the peptide’s potential effects on cartilage repair and osteoarthritis (an area where some preliminary research has been conducted), optimal dosing for subcutaneous administration, long-term safety profiles, and potential interactions with other metabolic compounds or peptides.
For now, AOD-9604 remains a research compound with